Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
      • T-Cell Adaptive Vaccine
      • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
      • Technical Support Position
  • Contact Us
  • Menu Menu
You are here: Home1 / Technology

Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines:

  • Emergex has successfully generated a 1st generation human-specific MHC class I CD8 peptide ‘ligandome’ library for Dengue, Influenza, Zika, Hepatitis B and Francisella tularensis, i.e. pathogen-derived peptides known to be presented to CD8+ T cells in the context of MHC class I molecules on the surface of pathogen-infected cells. The peptides are presented by the most commonly occurring HLA alleles, allowing for an estimated 95% population coverage by vaccine peptides. The ‘ligandome’ library contains encrypted peptide data to instruct the immune system to increase the frequency of pathogen-specific T cells, thereby increasing the base level of pathogen-specific immunity. Upon subsequent encounter with the pathogen, the immune system will have been pre-programmed to response more rapidly and with a larger number of pathogen-specific T cells. This will potentially reduce disease severity but still allow natural immunity to provide long-term protection.
  • Experimentally-validated peptides are combined with a quantum-sized nanocluster that can directly deliver them to the naive immune system and programme it to eliminate pathogen-infected cells upon subsequent exposure and infection. It is the combination of these technologies that produces a T-Cell Adaptive Vaccine, capable of delivering the right peptides to the right place, in order to induce a strong T cell immune response that will target and kill infected cells.
  • Emergex’s vaccines are suited to be administered by novel microneedle technologies.
  • Emergex’s vaccines do not need an adjuvant and potentially avoid allergic, autoimmune or antibody-mediated side effects, limitations associated with traditional vaccines.
Learn more about the advantages of our technology
Find out about ‘T-Cell Adaptive Vaccines’

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top